John Mascarenhas, ASH 2022: Treatment challenges in myelofibrosis and severe thrombocytopenia and the rationale for the use of pacritinib
Treatment options for myelofibrosis and severe thrombocytopenia are restricted due to high occurrences of JAK inhibitor-related thrombocytopenia. Pacritinib offers benefits for those patients with cytopenias. In this touchONCOLOGY interview, we speak with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) to discuss the challenges in the treatment of patients with myelofibrosis and the rationale for the use of pacritinib in these patients.
The abstract entitled ‘PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia’ (Abstract #4316) was presented at ASH Annual Meeting, 10–13, December, 2022.
Questions:
- What are the challenges in the treatment of patients with myelofibrosis? (0:16)
- What is the rationale for the use of pacritinib in these patients? (0:44)
Disclosures: John Mascarenhas is a consultant for Abbvie, BMS, CTi Bio, Galecto, GSK, Incyte Roche, Kartos, Karyopharm, Morphosys, Novartis and PharmaEssentia. He has received grant/research support from Abbvie, BMS, CTI, Incyte, Kartos, Novartis and PharmaEssentia.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ASH 2022
Access more content on Haematological Malignancies and Leukaemia
